Santen Pharmaceuticals-backed Clearside, which has raised $48m altogether, is developing a range of treatments for blinding eye diseases.
Clearside Biomedical, a US-based eye disease treatment developer that counts Santen Pharmaceuticals among its investors, completed a $20m series C round today.
The round was funded by Aju IB Investment, which acts as a subsidiary of financial services firm AJU Capital, Cormorant Asset Management, Perceptive Advisors, Rock Springs Capital Management and undisclosed existing Clearside investors.
Clearside is working on drug therapies for the treatment of eye diseases that cause blindness, and which will be delivered through the proprietary microinjector it…
